cyrilzakka/clinical-trials huggingface dataset:
The Physical and Psychological Benefits of Yoga and Breast Cancer

Breast Cancer is the most common cancer amongst Canadian women. Studies report that breast cancer patients are the most likely to use complementary medicine within the oncologic population. Yoga has become especially popular with this group as it promises to improve the mind, body and soul holistically. The investigators yoga program specifically focuses on rebuilding physical strength, increasing flexibility and reducing the pain and stress associated with the post-operative period. This study will examine how yoga can help improve the overall quality of life and its effects on the physical well-being of women with breast cancer. With positive statistical results, the investigators hope to implement yoga as part of their rehabilitation services at the Cedars Breast Clinic.

Proposed Intervention:

1-hour hatha yoga classes, once a week for a 12-week period. One class will be offered in French, another in English. The class will begin with approximately 10 minutes of pranayama (breathing exercises) and meditation, followed by 30 minutes of yoga poses and ending with 10 minutes of sivasana (rest period.) The first couple of classes in the 12 week series will begin with restorative postures and will gradually progress to more gentle exercises. If health permits, the last couple of classes will involve some strengthening poses. A small portion of the class will work with the physical body in general and there will be a specific emphasis on the physical difficulties faced by most breast cancer patients, i.e. neck, chest, shoulders arms and hands.

Eligibility Criteria:
Inclusion Criteria:

* Ages between 18-70
* Stage I to II breast cancer
* Minimum of 6 weeks Post Operative status

Exclusion Criteria:

* Previous/Current psychiatric history
* Concurrently involved in a yoga program
* Inability to undergo yoga training secondary to physical/health limitations outlined by the treating team
MESNA Injection for TMJ Internal Derangement

The pathogenesis of temporomandibular disorders focusing on the biochemistry of the synovial fluid in various stages of temporomandibular joint disease. The role of inflammation has been investigated and proposed as an underlying mechanism of pain and dysfunction of temporomandibular joint. MESNA (sodium 2-mercaptoethanesulfonate) was approved several years ago and marketed in several formulations as a mucolytic agent in the respiratory field, since it breaks the disulfide bonds between polypeptide chains of mucus. The tissue distribution of MESNA is negligible, and the elimination of the substance is rapidly and completely achieved by kidney


Eligibility Criteria:
Inclusion Criteria:

* patients with TMJ internal derangement with reduction

Exclusion Criteria:

* inflammatory or connective tissue disease
* autoimmune disease history
* neurologic problems
The Effects of Nitrate Supplementation on Elite Runners

This study analyzed the effects of 15 days of beetroot juice supplementation on different performance measures in elite Spanish distance runners

This study analyzed the effects of 15 days beetroot juice supplementation on the VO2max, running economy, exercise perceived exertion, muscle power and locomotion mechanics in a group of 12 elite Spanish middle and long distance runners

Eligibility Criteria:
Inclusion Criteria:

* Competing in national and international events
* Personal best in urban 10k: 33 minutes 0 seconds

Exclusion Criteria:

* Injury
Midurethral Sling With Autologus Rectus Sheath

assessment of the safety and efficacy surgeon tailored rectus sheath midurethral sling

the rectus sheath is harvested in 5 cm length and 2 cm width , A 2cm width 8 cm length polypropolyine mesh is attached to the harvest rectus sheet sling on both side The procedure is carried with a similar technique to the outside in TOT.

Eligibility Criteria:
Inclusion Criteria:

* stress incontinence

Exclusion Criteria:

* overactive bladder
Effect of Linagliptin on Insulin Sensitivity and Pancreatic Beta Cell Function in Patients With Type 2 Diabetes Mellitus

This study is planned to evaluate if linagliptin can improve insulin sensitivity in patients with type 2 diabetes mellitus. In addition, the effect of linagliptin on pancreatic function will be studied.

This is a prospective study of 30 patients with type 2 diabetes mellitus (T2DM) . Patients with T2DM in the age group 30-65 years and duration of diabetes less than five years will be screened. After exclusion, those who meet the inclusion criteria will be included in the study.

Once eligibility criteria are confirmed, patients will be educated about their disease and will be advised weight maintenance diabetic diet and exercise throughout the study period. Patients will be randomized to three groups - linagliptin (5mg OD) or voglibose (0.2mg TDS) or placebo OD. Metformin will be continued in all patients. To evaluate the effect of linagliptin on insulin sensitivity and beta cell function, independent of changes in HbA1c, the voglibose group is included. Each group will have 10 patients and will be followed up for 6 months. Both patients and physicians will be blinded to the treatment.

After having written informed consent, a detailed history and a thorough clinical examination will be done in all subjects including measurement of height, weight, body mass index and waist circumference. Hemoglobin, liver function tests, renal function tests, lipid profile, HbA1c, fasting plasma insulin , C-peptide, homeostasis model assessment-insulin resistance index(HOMA-1R) and homeostasis model assessment-beta cell function index (HOMA-β) will be done at baseline. A euglycemic hyperinsulinemic clamp study and a mixed meal test will be performed in all patients (on different days) at baseline and after 6 months of follow up. Biochemical parameters will be measured again 6 months after therapy. Fasting and post-prandial blood glucose will be done monthly for 6 months.

Eligibility Criteria:
Inclusion Criteria:

* Patients with type 2 diabetes mellitus (according to ADA guidelines)
* Age between 30-65 years
* Duration of diabetes less than five years
* BMI of between 20 and 40 kg/m2
* HbA1c level of \< 7.5%
* On metformin monotherapy for at least 6 weeks

Exclusion Criteria:

* History of ketoacidosis
* Hepatic impairment (defined as plasma aminotransferase elevations of more than 3 times upper limit of normal)
* Renal failure (defined as Serum Creatinine more than 1.5 mg/dl)
* Coronary artery disease or heart failure
* Cerebrovascular disease or stroke
* Anemia (Hb\< 10 g/dl)
* Those who requires insulin therapy HbA1c \>7.5%
* Presence of macular edema
* Pregnant or lactating women
* Patients who have received dipeptidyl peptidase 4 (DPP-4) inhibitor therapy within last 3 months
Adequacy of Antenatal Care and Its Determinants in Assiut District

Cross sectional study on women who gave birth and attend immunization session for their children in Assiut District to assess the adequacy of ANC, its determinants and knowledge and attitude of antenatal care among the studied women

The World health organization (WHO) estimated that worldwide in 2021, about 211 women died per 100,000 live birth from pregnancy related causes and increasing to 415 on average in the poorest countries (1)Globally in 2020, nearly 2.4 million babies died during the first 28 days of life (2). High coverage of quality Antenatal Care (ANC) can play a crucial role to decrease maternal and child mortality rates and achieve national and global targets related to maternal and child health. ANC received from skilled provider increases maternal and newborn survival and reduces the risk of pregnancy complications and adverse pregnancy outcomes(3) .

New WHO guidelines on antenatal care for a positive pregnancy experience include:

1. A minimum of eight contacts are recommended.
2. Counselling about healthy eating and keeping physically active during pregnancy.
3. Daily oral iron and folic acid supplementation
4. Tetanus toxoid vaccination is recommended.
5. One ultrasound scan before 24 weeks' gestation.
6. Health-care providers should ask all pregnant women about their use of alcohol and other substances(4).

The 2016 WHO prenatal care guidelines for a healthy pregnancy experience reflect a change from the centered ANC model with a prescribed minimum of 4 ANC visits (ANC4+) to a more expanded model that emphasizes contact number, timing, and services(5). At the global and national levels, most currently available data indicate that women receive at least 4 antenatal care visits. There is very limited data on the adequacy of ANC based and their correlates on updated WHO recommendations for antenatal care(5, (6),(7)). The current study is conducted in accordance with the research plan of Public Health and Community Medicine Department- Faculty of Medicine, Assiut University.

Eligibility Criteria:
Inclusion Criteria :

women of reproductive age who gave birth

-

Exclusion Criteria:

Pregnant and menopaused women
Effect of a Nursing Teaching Protocol on Mastitis Prognosis: Quasi-Experimental Research Design

Aim: Evaluate the effect of a nursing teaching protocol on mastitis prognosis. Research design: Quasi-experimental research design was utilized. A convenient sample of sixty adult female patients diagnosed with mastitis, Patients divided equally into two groups(study and control) thirty for each.

The study was conducted in the breast unit in general surgery department at Main Assiut University Hospital. A convenient sample of sixty adult female patients diagnosed with mastitis, their ages range from 20 to 65years old. Patients divided equally into two groups; thirty for each. Both groups had been assessed at base line using the following tools:

Tool (I): An interview questionnaire sheet Tool (II):Mastitis self-care practices Tool (III): Numeric pain rating scale Tool (IV): Mastitis prognosis sheet

The control group exposed to routine care and study group received mastitis teaching protocol. After three weeks; both groups had been reassessed by the same tools.

Data analysis had been performed by using the Statistical Package for the Social Sciences (SPSS) Categorical variables described by number and percent (N, %). Continuous variables described by mean and standard deviation (Mean, SD). Chi-square test and Fisher exact test used to compare between categorical variables .T-test and Pearson's chi-square used to appear the association between patients' knowledge, practice, and mastitis prognosis before implementation of nursing teaching protocol and three weeks post.

Eligibility Criteria:
Exclusion Criteria:

1. Mental health problems
2. Visual or hearing problems
3. Uncooperative
Efficacy and Safety of Zactima™ in Patients With Castration-refractory Metastatic Prostate Cancer

This randomized, double-blind phase II trial is to assess the efficacy and safety of bicalutamide (Casodex® ) associated to ZD6474 (Zactima™ ) or to placebo in patients with castration-refractory metastatic prostate cancer without any clinical symptom related to disease progression. The study is blinded, and subjects will be randomised (1:1 ratio) to either ZD6474 300 mg or placebo. The blinded design ensures robust, unbiased data collection and assessment. Placebo control is necessary to ensure a robust assessment of PSA PFS, and is acceptable in this subject population where all subjects will also received bicalutamide 150 mg o.d. Subjects will continue study treatment until they reach objective biological disease progression or unacceptable toxicity or withdrawal of consent or until end of trial (which event occurs first). The end of study is fixed 12 months after the last randomised patient's first dose of study treatment.


Eligibility Criteria:
Inclusion Criteria:

* Males presented with a confirmed histological diagnosis of adenocarcinoma of the prostate with evidence of metastases (including bone, lymph nodes, or other site) radiologically or histologically documented and despite a serum testosterone ≤1.73 nmol/L (50 ng/dL) proving castration, evidence of biochemical progression of prostate cancer, documented by a rise in PSA .

Exclusion Criteria:

* Radiotherapy or surgery or antiandrogens (except LHRH analogue) or bilateral orchiectomy within the 30 days preceding Visit 1. Incompletely healed surgical incision.
* Concomitant anticancer therapy other than surgical castration or continuous medical castration.
* Biology restriction.
* Clinical significant cardiovascular event or presence of cardiac disease that in the opinion of the Investigator increases the risk of ventricular arrhythmia.
* History of arrhythmia which is symptomatic or requires treatment (CTCAE grade 3), symptomatic despite treatment, or asymptomatic sustained ventricular tachycardia. Subjects with atrial fibrillation controlled on medication are permitted.
* Hypertension not controlled by medical therapy
* ECG /QTc prolongation
* Presence of left bundle branch block (LBBB).
Project to Promotion of Breastfeeding

Breastfeeding is the ideal feeding for the newborn. The success of the initiation and maintenance of breastfeeding can be influenced by different factors, as breastfeeding self-efficacy. Brief Motivational Intervention (BMI) is a form of collaborative guidance, person-centered approach aimed at strengthening the motivation to adopting healthy initiatives and can increase the self-efficacy.

The hypothesis is that an BMI to promote breastfeeding, during immediate postpartum plus telephone support at the first and third postpartum months, will significant increase in the adherence and duration of breastfeeding compared with the habitual education action applied at the same time. Also, the BMI will increase the breastfeeding self-efficacy of the particpants, and this breastfeeding self-efficacy will be a mediator of the effect between the IMB and the breastfeeding duration.

The general self-efficacy of the participants will change the size of the effect of BMI.


Eligibility Criteria:
Inclusion Criteria:

* All women with term gestations who have given birth healthy newborns by vaginal delivery at the hospital .who agree to participate in the study by signing informed consent, will be includes in the study

Exclusion Criteria:

* Mothers who, by medical indication or own decision, do not initiate breastfeeding in the first hour of the newborn's life.
* Mother of children who require admission to the neonatal unit.
* Women with a previously diagnosed psychiatric disorder.
* Neurological or cognitive impairment that impedes the evaluation and the BMI
* Resident status that prevents correct follow-up of patients (eg. residence outside Spain).
* Women with language or communication barriers
Knowledge and Attitude About HPV Vaccines

The purpose of this study was to analyze the knowledge and attitude about HPV vaccines among Brazilian women after an educative intervention. The knowledge was measured on sexual behavior and HPV infection. The attitude was measured on acceptance of vaccines.

Two hundred Brazilian women were selected ranged 18 to 30 years old. They were randomized on two groups: 1) One hundred received a brief educative intervention about HPV infection and vaccines and answered a questionaire about sexual behavior, HPV infection and vaccines and 2)one hundred not received anything and answered the same questionaire.

Eligibility Criteria:
Inclusion Criteria:

* healthy women

Exclusion Criteria:

* previous CIN or cervical cancer treatment
Evaluate the Post-marketing Efficacy and Safety of Eptq S and Eptq Lidocaine S

This study in multi-center, prospective and observational study. The purpose of this study is to observe effects and safety of hyaluronic acid filler series, eptq S and eptq Lidocaine S, for facial volume and folds.

Participants for this study are treated with eptq S and eptq Lidocaine S for smoothing nasolabial folds or volumizing mid-face or lips. Treating period is around 24 weeks. Facial volume and wrinkle condition, participants' satisfaction, and safety would be assessed.

Eligibility Criteria:
Inclusion Criteria:

* Male and Female adults aged 19 years and older.
* Meet one of the following among individuals who want temporary improvement of facial wrinkles and volume.

  1. Wrinkle Severity Rating Scale score 3 or 4 for Nasolabial fold.
  2. Mid-Face Volume Deficit Scale score 3 or greater.
  3. Medicis Lip Fullness Scale score 1-2. In cases of 2-1) and 2-2), participants must meet both sides (right and left) to be eligible for enrollment.

     For 3), the Medicis Lip Fullness Scale scores 1-2 at the target sites for procedures (upper lip, lower lip, up \& down) eligible for enrollment
* Voluntarily agree to participate in this observational study in written consent form.

Exclusion Criteria:

* Received anti-thrombotics (except low-dose aspirin \[100 mg, maximum 300 mg/day\]) within 2 weeks from screening.
* Currently have or have a history of bleeding disorder.
* applied graft/prosthesis or biomaterials, including hyaluronic acid, polycaprolactone, collagen filler, lifting (threads, laser, etc.), and Botulinum toxin, at the site for indication within 24 weeks from screening.
* Skin disorder or wound infection on the face that affects this study
* Have history of side effects of EMLA cream or equivalent lidocaine agent.
* History of hypersensitivity to hyaluronic acid agent(s).
* Other contraindications as per the \[Precautions for Use\] in the approved label for the study device.
* Determined as not eligible for the study by the investigator.
A Study to Investigate Whether the Immediate Use or Deferred Use of an Anti-viral Drug Lamivudine Will Help to Better Safe-guard the Delivery of Chemotherapy in Patients With Cancer Who Are Also Hepatitis B Carriers

Patients with non-lymphoma and non-leukaemia cancer who are also hepatitis B carriers will have a risk of hepatitis B reactivation during chemotherapy. Lamivudine can be used effectively to control hepatitis upon reactivation during chemotherapy and the chemotherapy may not need to be interrupted. The study aims to investigate whether adding the anti-viral drug Lamivudine at the start of chemotherapy for all patients, rather than at the time of hepatitis reactivation for those with reactivation, will help to improve the delivery of chemotherapy in these patients.


Eligibility Criteria:
Inclusion Criteria:

1. Patient with histology-proven malignant solid tumor other than malignant lymphoma
2. Patients with age between 18 and 75
3. Patients with Karnofsky performance score (KPS) of at least 60
4. Patients planned for at least 4 cycles of intensive cytotoxic chemotherapy (either as part of curative therapy or as palliative therapy), except for those receiving single agent cisplatin chemotherapy alone concurrently with radiation for radiosensitization
5. Patients with at least 6 months' life expectany from date of recruitment
6. Patients with normal liver function tests including alanine aminpotransferase (ALT), alkaline phosphatase (ALP), gamma glutamyl-transpeptidase (GGT), and bilirubin
7. Patients with no known history of radiological \&/or histological diagnosis of chronic active hepatitis or cirrhosis of any cuase, or history of prior hepatitis B reactivation, or prior chronic therapy for HBV within 6 months
8. Patients with no evidence of autoimmune hepatitis, hepatitis C or delta virus infection, HIV infection or radiological evidence of liver metastasis
9. Patients with negative pregnancy test for female gender of child-bearing age

Exclusion Criteria:

1. Patients with age \< 18 and \> 75
2. Patients with Karnofsky performance score (KPS) of \< 60
3. Patients planned for single agent cisplatin chemotherapy alone concurrently with radiation for radiosensitization
4. Patients with \< 6 months' life expectancy from date of recruitment
5. Patients with abnormal liver function tests including alanine aminotransferase (ALT), alkaline phosphatase (ALP), gamma glutamyl- transpeptidase (GGT), and bilirubin
6. Patients with known history or radiological and/or histological diagnosis of chronic active hepatitis or cirrhosis of any cause, or history of prior hepatitis B reactivation, or prior chronic therapy for HBV within 6 months
7. Patients with autoimmune hepatitis, hepatitis C or delta virus infection, HIV infection or radiological evidence of liver metastasis
8. pregnant female patients
A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), Food Effect of AMG 357 in Healthy Subjects

Study to evaluate the safety, tolerability, PK, PD, and food effect of AMG 357 in healthy subjects


Eligibility Criteria:
Inclusion Criteria:

* Healthy Adult subjects between 25 and 55 years old
* Body mass index (BMI) between 18 and 32 kg/m2
* Normal or clinically acceptable physical examination, clinical laboratory values, and ECG
* Additional inclusion criteria apply

Exclusion Criteria:

* Any history or evidence of a clinically significant disorder, condition or disease that would pose a risk to subject safety.
* Additional exclusion criteria apply
Modified Müller's Muscle-conjunctival Resection Internal Ptosis Repair Using Fibrin Glue

Fibrin glue is widely used in ophthalmology for homeostasis and tissue recovery. It is commonly used in ocular surface surgeries such as pterygium removal and conjunctival lesions excisions. In Müller's muscle-conjunctival resection (MMCR), sutures are used to reconnect the conjunctiva and Muller muscle, which causes discomfort and pain for the patient. The investigators' goal is to explore using fibrin glue instead of sutures in MMCR surgeries to shorten the procedure's length and alleviate patients discomfort and pain. This is especially important in the management of children suffering ptosis, where sedation and even general anaesthesia is required for sutured removal as a secondary procedure.

Fibrin glue is widely used in ophthalmology for homeostasis and tissue recovery. It is commonly used in ocular surface surgeries such as pterygium removal and conjunctival lesions excisions.

Müller's muscle-conjunctival resection (MMCR) is the most common surgery for ptosis correction and is normally performed under local anaesthesia. In MMCR, a portion of the Muller and conjunctiva is resected, and sutures are used to reconnect the remaining edges. The suturing process requires several minutes and causes discomfort to the patient. In addition, many patients experience post operative discomfort due to the touch of the sutures in the superior ocular surface until their removal about 7-14 days post op. Moreover, the sutures removal process is commonly unpleasant, and in the pediatric patients requires sedation or general anaesthesia.

The investigators' goal is to explore using fibrin glue instead of sutures in MMCR surgeries to shorten the procedure's length and alleviate patients discomfort and pain. This is especially important in the management of children suffering ptosis, where sedation and even general anaesthesia is required for sutured removal as a secondary procedure.

Methods:

A prospective randomized study. Patients will be randomized into traditional MMCR using sutures, vs. MMCR using tisseel glue. Follow up will take place 1 day, 7 days, 1 month and 3 months post op. Main outcome measures included patient reported outcome such as pain grade and discomfort, and success of ptosis repair surgery defined by improvement in margin reflex distance, symmetry of upper eyelid position, and incidence of complications.

Eligibility Criteria:
Inclusion Criteria:

Patients with ptosis referred to Müller's Muscle-Conjunctival Resection (MMCR)

Exclusion Criteria:

Previous eyelid surgery